CAMBRIDGE, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (SURF) (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results